AUTHORS
Shinnosuke Matsueda, PhD, Sachiko Tai, PhD2, Reina Takeda, PhD3, Junko Iwano, PhD4, Hiroko Takahashi, MS5, Yuko Nakajima, MS6, Janakan Sam Narean, MS7, Tomasz Zabinski, MS8, Stuart Ellison, PhD9, Pervinder Sagoo, PhD10, Shin-ichiro Takayanagi, PhD11
AFFILIATIONS
1 Kyowa Kirin Co., Ltd., Shizuoka, Japan
2 Kyowa Kirin Co., Ltd., Shizuoka, Japan
3 Kyowa Kirin Co., Ltd., Shizuoka, Japan, Kyowa Kirin Co., Ltd., Tokyo, Japan
4 Kyowa Kirin Co., Ltd., Shizuoka, Japan
5 Kyowa Kirin Co., Ltd., Shizuoka, Japan
6 Kyowa Kirin Co., Ltd., Tokyo, Japan
7 Orchard Therapeutics (Europe) Ltd., London, United Kingdom
8 Orchard Therapeutics (Europe) Ltd., London, United Kingdom
9 Orchard Therapeutics (Europe) Ltd., London, United Kingdom
10 Orchard Therapeutics (Europe) Ltd., London, United Kingdom
11 Kyowa Kirin Co., Ltd., Shizuoka, Japan, Kyowa Kirin Co., Ltd., Tokyo, Japan
ABSTRACT
Current conditioning regimens for hematopoietic stem cell transplantation (HSCT) and hematopoietic stem cell gene therapy (HSC-GT) rely on agents such as busulfan (BU), or total body irradiation (TBI). These non-specific agents cause broad tissue damage, resulting in both short and long-term complications, including the risk of infertility and serious clinical complications. Use of a monoclonal antibody (Ab) targeting the CD117 receptor (c-Kit) for stem cell factor (SCF), expressed on HSC and progenitor cells (HSPCs), offers a reduced toxicity conditioning approach to overcome these issues, through blockade of SCF/c-Kit signaling, which is crucial for HSC survival, proliferation, and niche retention.
This concept has been investigated with c-Kit blocking Abs, clone ACK2 in mice and briquilimab in humans. Although promising in some clinical settings, its ability to achieve effective donor engraftment has been variable, possibly reflecting differences in disease biology and the need for combination with other conditioning agents. Preclinical evaluation has largely relied on ACK2, a rat IgG2b (rIgG2b) Ab which exerts Fc-dependent effector functions in mice, whereas briquilimab carries an N297A modification to attenuate effector functions. Thus, the use of ACK2 in mice may deplete HSCs through effector-mediated cytotoxic mechanisms such as antibody-dependent cell-mediated cytotoxicity (ADCC), potentially leading to an overestimation of the efficacy of c-Kit blockade as a conditioning strategy.
Here, we describe the development of a surrogate ACK2 antibody, engineered to block mouse SCF/c-Kit signaling without Fc-mediated effector activity, enabling more robust in vivo modelling of this reduced toxicity conditioning approach.
To engineer the Fc region of ACK2, immunoglobulin variable regions were cloned from hybridoma and introduced into human IgG (hIgG) or rIgG2b backbones with effector-attenuating mutations, generating 5 engineered variants. All variants showed reduced binding to mouse Fcγ receptors and C1q relative to parental ACK2, indicating attenuated potential for ADCC and complement-dependent cytotoxicity. Antibody engineering retained the c-Kit blocking activity of parental ACK2, confirmed by binding assays using the c-Kit expressing cell line MC/9, and SCF/c-Kit-dependent proliferation assays using mouse lineage-negative (Lin-) bone marrow (BM) HSPCs.
Pharmacokinetic studies in mice injected with engineered Abs (iv, 25 mg/kg) demonstrated that a hIgG4 backbone harboring the S228P/L235E/R409K mutations (hIgG4 PEK) achieved serum exposure exceeding 3 μg/mL at 96 hours post-administration, over 10-fold higher than the other four variants each bearing either L234A/L235A/P329G or N297A mutations in the rIgG2b or hIgG1 backbones. Flow cytometric analysis confirmed binding to c-Kit+ BM cells for > 5 days post-administration. Furthermore, ACK2 hIgG4 PEK treatment reduced peripheral blood cell counts at 6 days post-administration, including red blood cells, lymphocytes, and neutrophils, confirming in vivo functional activity consistent with the role of SCF/c-Kit signaling in hematopoiesis. These findings indicate that ACK2 hIgG4 PEK exhibits reduced Fc-mediated binding to Fcγ receptors and C1q, a favorable pharmacokinetic profile, and effective suppression of SCF/c-Kit signaling at the multipotent HSPC level.
We then evaluated ACK2 hIgG4 PEK as a conditioning agent in combination with BU and TBI. A single dose of ACK2 hIgG4 PEK (iv, 25 mg/kg, day 0) decreased phenotypic long-term HSC (LT-HSC; Lin⁻c-Kit⁺Sca-1⁺CD48⁻CD150⁺) numbers in BM by nearly 90% relative to untreated mice at day 6. Depletion was further enhanced in combination with reduced-dose BU (4 intraperitoneal doses, total 25 mg/kg, days 2–5) or reduced-intensity TBI (X-ray, 2 Gy, day 5). Combination regimens achieved depletion almost comparable to those obtained with standard myeloablative conditioning (10 Gy TBI and 100 mg/kg BU).
These preclinical results show that combined use of anti-CD117 Ab and reduced intensity conditioning regimens can deliver effective HSC depletion, supporting effective donor engraftment in an immune replete transplant setting.
In summary, ACK2 hIgG4 PEK provides a unique tool to isolate the biological contribution of SCF/c-Kit signaling blockade from Fc-mediated HSC depletion, establishing a more clinically predictive framework for anti-CD117 conditioning and accelerating its translation toward reduced-toxicity HSCT and HSC-GT.
DISCLOSURES
Shinnosuke Matsueda, PhD: Kyowa Kirin Co., Ltd. - Current Employment; Asahi Kasei Therapeutics Corporation - Current Employment